PharmaBiz Tue, 20 Jan 2009 4:36 AM PST
Peptimmune, Inc, a privately held biotechnology company, has granted Novartis an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate.
My Ms Miracle Glasgow Daily Record - Glasgow,Scotland,UK A MULTIPLE sclerosis sufferer is celebrating the "miracle" birth of her son after she was given IVF treatment. Laura Lawes admits she thought her life was ... See all stories on this topic |
Virat will triumphs over disability Daily News & Analysis - Mumbai,India Not even multiple sclerosis (MS), which he was diagnosed with in 1999 and which left him wheelchair-bound, has come in the way of his aspirations. ... See all stories on this topic |
Connecticut teams move society toward a cure Norwalk Plus Magazine - USA DeFord was diagnosed with multiple sclerosis (MS) in September 2007. Just five months later she had decided to join the movement against the disease by ... |
- Risk factors for multiple sclerosis
- OPEN TOPIC - Medical Syringe - Waste
- The Multiple Sclerosis Severity Score (MSSS) predi...
- The role of genes in the pathogenesis of MS
- VISUAL Problems and MS
- EXTAVIA Approved In European Union For Treatment
- Interferon Delivered via a Nasal Spray
- Paly student researches potential cure for MS
- Trauma of teenage years tougher for those coping
- An Author, Doctor, Mother, and Patient - Over...
e-Newsletter Disclaimer:
***Editor's Note: The intent of this newsletter is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
No comments:
Post a Comment
Leave comments only that directly pertain to each article.
All solicitations will be removed.